Mount Sinai Launches Pilot Study on Chemotherapy vs. Surgery for Stage II/III Rectal Cancer
The Quicksilver II pilot study will evaluate if patients with margin-clear Stage II or III rectal cancer can safely skip neo-adjuvant chemotherapy.
Asset / Drug
Drug and asset intelligence for Mount with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.